CAJ | 학술논문

外周T细胞淋巴瘤(peripheral T-cell lymphonla,PTCL)是亚洲国家发病率较高的非霍奇金淋巴瘤.T细胞淋巴瘤各亚型具有明显的异质性,疗效和预后截然不同.目前尚没有标准的治疗方案.传统的治疗多采用CHOP或CHOP样方案,但疗效欠佳.第二、三代剂量强度方案(m-BACOD、ProMACE-CytaBOM及MACOP-B方案)与CHOP方案比较,并未显示出生存优势.新的治疗研究包括细胞毒性药物吉西他滨,无论是作为一线治疗还是针对复发和难治的PTCL患者都显示出了良好的疗效,有望成为治疗PTCL,患者的新策略.阿仑单抗在PTCL的治疗中取得良好的效果.Zanohmumab单抗在复发和难治PTCL Ⅱ期临床试验中疗效突出.地尼白介素、新型抗叶酸药Pralatrexate、蛋白酶体抑制剂硼替佐米及抗血管生成药物贝伐单抗在Ⅱ、Ⅲ期临床试验中显示了颇有前景的疗效.自体干细胞移植可作为具有高危因素的PTCL患者缓解后的巩固治疗.
외주T세포림파류(peripheral T-cell lymphonla,PTCL)시아주국가발병솔교고적비곽기금림파류.T세포림파류각아형구유명현적이질성,료효화예후절연불동.목전상몰유표준적치료방안.전통적치료다채용CHOP혹CHOP양방안,단료효흠가.제이、삼대제량강도방안(m-BACOD、ProMACE-CytaBOM급MACOP-B방안)여CHOP방안비교,병미현시출생존우세.신적치료연구포괄세포독성약물길서타빈,무론시작위일선치료환시침대복발화난치적PTCL환자도현시출료량호적료효,유망성위치료PTCL,환자적신책략.아륜단항재PTCL적치료중취득량호적효과.Zanohmumab단항재복발화난치PTCL Ⅱ기림상시험중료효돌출.지니백개소、신형항협산약Pralatrexate、단백매체억제제붕체좌미급항혈관생성약물패벌단항재Ⅱ、Ⅲ기림상시험중현시료파유전경적료효.자체간세포이식가작위구유고위인소적PTCL환자완해후적공고치료.
The incidence rate is high in Asia country, accounting for 15 %-20 % of Non-Hodgkin lymphoma. Every phynotype has different heterogeneity, therapeutic effect and prognosis are also different. There is no standard rigemen for T cell lymphoma at present. CHOP like regimen is commonly used. But therapeutic effect is not as good as we expected. Clinical research shows that dose and intensity regimen, such as m-BACOD,ProMACE-CytaBOM, MACOP-B, do not exhibit survival advantage compared with CHOP regimen. New treatment includes cytotoxic drug, such as gemcitabine. As first line therapy for T cell lymphoma or as salvage therapy for refractory or relapsed T cell lymphoma, the therapeutic effect is good. Gemcitabine based regimen is new for PTCL. Alemtuzumab is a humanized CD52 mono-clonal antibody and is expected as good effect on PTCL therapy. Zanolimumab is a humanized mono-clonal antibody which targets CD4 antigen on T cell. Phase Ⅱclinical research has also got good effect. Denileukin difiitox and Pralatrexate also have good effect on PTCL therapy in clinical researches. Autologous stem cell transplantation(ASCT) is also used in PTCL therapy.